← All posts The Génie Talks

Decoding diabetes: how genomics is shaping the future of screening and management

By Srishti Sudan · 2 Dec 2025 · 2 min read

For years, diabetes has been seen primarily as a lifestyle condition: the result of diet, exercise, and everyday habits. Yet, beneath these surface-level factors lies a deeper layer: your genes. Advances in genomics have revealed that our DNA plays a crucial role in determining how prone we are to diabetes, how it develops, and how our body responds to treatment.

At Genique Lifesciences, we believe that understanding your genome is the key to transforming diabetes management from reactive to proactive.

The genetic blueprint behind diabetes

While Type 1 Diabetes is largely autoimmune, Type 2 Diabetes, the most common form, arises from a complex interaction between genes and lifestyle factors. Scientists have identified over 400 genetic variants linked to diabetes, influencing insulin production, glucose regulation, and fat metabolism.

For instance, variations in genes such as TCF7L2, PPARG, and KCNJ11 can affect how efficiently the body uses insulin or processes glucose. This genetic variability explains why two people with similar routines can experience completely different health outcomes, because their DNA defines their baseline risk.

Genomic screening: detecting risk before it manifests

Traditional diabetes screening methods such as blood glucose and HbA1c tests, detect the condition only after physiological changes occur. Genomic screening, however, identifies predispositions much earlier.

By evaluating multiple gene variants through a Polygenic Risk Score (GRS), genomic testing estimates an individual's inherited likelihood of developing diabetes. When combined with environmental and lifestyle data, it creates a comprehensive risk profile.

At Genique Lifesciences, this proactive approach helps individuals make targeted lifestyle adjustments long before diabetes develops, turning awareness into prevention.

Personalised management through genomic insight

Genomics also reshapes how diabetes is managed after diagnosis. Certain gene variants affect how patients metabolise medications like metformin, influencing efficacy and side effects. Genetics can guide nutrition strategies, helping determine whether an individual benefits more from a low-carb, Mediterranean, or high-fibre diet. Even exercise response and glucose utilisation patterns are genetically influenced.

By combining these insights, personalised diabetes care becomes a reality, ensuring each plan aligns with an individual's genetic profile for maximum effectiveness.

Empowerment through early insight

For individuals with a family history of diabetes, Genique Lifesciences' genomic screening offers clarity, direction, and empowerment. It helps identify inherited risks before symptoms appear, enables early preventive action through tailored recommendations, and supports precision treatment based on genetic response.

For healthcare professionals, integrating genomic data enhances preventive care, allowing for proactive and precise patient support.

The genomic era of diabetes care

The future of diabetes care lies in personalisation, and genomics is leading that transformation. By decoding how genes influence disease susceptibility, drug response, and metabolic efficiency, we can shift diabetes care from management to prevention.

At Genique Lifesciences, we're bridging the gap between genetics and everyday wellness. Through genomic screening, we empower individuals to understand their risks, personalise their care, and take control of their health journey.

Because when it comes to diabetes, your genome doesn't just hold the risk; it holds the roadmap to prevention.

Want to know your inherited risk?

GeniqueCARE DCVD screens the variants behind diabetes and cardiovascular disease.

Talk to our team

Srishti Sudan, Product Manager

Srishti Sudan is a product manager at Genique leading field application and product marketing. She has operated multiple NGS and array platforms and is a keen reader.

This article is for general and professional information. It is not medical advice, and does not recommend any test or treatment for any individual. Genique Lifesciences distributes genomics technologies and provides bioinformatics and sample-to-report services to institutions on a business-to-business basis; it does not provide clinical or diagnostic services to patients. Questions about testing for yourself or a family member should be raised with a treating clinician or a certified genetic counsellor.

The Génie Talks
22 Apr 2026

The unfinished map: why whole genome is the new standard

The exome reads only the highlighted sentences. In the NICU, where hours decide a lifetime of outcomes, whole genome sequencing has become the standard of care rather than the upgrade.

Read · 4 min read → 30 Apr 2026

The molecular map: how genomic sequencing is rewriting the rules of medicine

Sequencing has gone from expensive scientific wonder to fundamental utility, dismantling the medicine of averages across oncology, pharmacology, reproductive health and rare disease.

Read · 4 min read → 4 May 2026

Shifting the paradigm: moving precision oncology from late-stage lifeline to early-stage cure

Precision oncology works, mostly at the stage where cure is no longer the goal. The biological case for moving it upstream is strong; the infrastructure to carry it is not there yet.

Read · 5 min read →
Let's talk

Set up an introduction meeting today.

Tell us about your lab and where you want to take it. We'll bring the right technology and team.

Email contact@genique.co Phone +91 124-426-3051
Office Unit-805, 8th Floor, Unitech Arcadia, South City-2, Sector 49, Gurugram, Haryana 122018

By submitting this form you consent to Genique Lifesciences processing the details above to respond to your enquiry, and to their retention for 24 months from our last contact. You may withdraw consent at any time by emailing contact@genique.co. See our Privacy Policy.